Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost
(Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in
compliance with Chinese SFDA regulation.